keyword
https://read.qxmd.com/read/38024614/real-world-multiple-myeloma-front-line-treatment-and-outcomes-by-transplant-in-the-united-states
#21
JOURNAL ARTICLE
Joshua Richter, Darren Pan, Taylor Salinardi, Megan S Rice
Stem cell transplantation (SCT) has been an integral treatment modality for multiple myeloma (MM) for decades. However, as standard-of-care therapies have improved, the benefit of SCT has been repeatedly called into question. This retrospective study evaluated the association between SCT in the first line of therapy (LOT) and outcomes for patients with newly diagnosed multiple myeloma (NDMM) in the United States. We included patients from a de-identified electronic health record-derived database who initiated front-line MM therapy between January 1, 2016, and January 31, 2022...
November 2023: EJHaem
https://read.qxmd.com/read/38010113/an-alternative-processing-approach-to-increase-cd138-intensity-in-flow-cytometric-analysis-of-plasma-cells
#22
JOURNAL ARTICLE
Deepak Kumar, F N U Kiran, Amanda Wheeler, Rory Dellamano, Richard D Hammer
BACKGROUND: Surface median immunofluorescence intensity (MFI) of plasma cells antigens, particularly CD138, by flow cytometry underestimates plasma cell populations when compared with that estimated by morphological assessment on Wright's-stained slides. CD138 MFI using traditional sample preparation methods for flow cytometric analysis is often dim and difficult to interpret due to multiple factors. This becomes critical when diagnosing and accurately classifying plasma cell dyscrasias...
November 27, 2023: Cytometry. Part B, Clinical Cytometry
https://read.qxmd.com/read/37984714/real-world-utilization-of-radiation-therapy-in-multiple-myeloma-an-analysis-of-the-connect%C3%A2-mm-registry
#23
JOURNAL ARTICLE
Leslie Ballas, Sikander Ailawadhi, Mohit Narang, Cristina J Gasparetto, Hans C Lee, James W Hardin, Brian G M Durie, Kathleen Toomey, James Omel, Lynne I Wagner, Rafat Abonour, Howard R Terebelo, Prashant Joshi, Edward Yu, Liang Liu, Robert M Rifkin, Sundar Jagannath
PURPOSE: Radiation therapy (RT) is an important treatment modality for patients with multiple myeloma (MM). While patients are living longer with MM, they are more likely to suffer from comorbidities related to treatment such as bone pain; however, RT can provide symptom relief. To date, the characterization of patients who have received RT in the real-world setting has been limited. METHODS: The Connect® MM Registry is a large, US, multicenter, prospective observational cohort study of adult patients with newly diagnosed MM from mostly community sites...
November 18, 2023: Practical Radiation Oncology
https://read.qxmd.com/read/37944334/femoral-metastatic-pathological-fractures-impending-and-actual-fractures-a-patient-survival-study
#24
JOURNAL ARTICLE
Oded Hershkovich, Mojahed Sakhnini, Gal Barkay, Boaz Liberman, Alon Friedlander, Raphael Lotan
INTRODUCTION: The skeleton is a common site for metastases. Prostate, breast, lung, renal and thyroid carcinomas account for 80 % of the original cancers, with the femur being the most affected long bone. With improved oncological treatments, prolonged patient survival leads to an increased prevalence of osseous metastases. This study examines the impact of preventive surgery for impending femoral pathological fracture (IFF), versus treatment of pathological femur fracture (PFF) on patient mortality and morbidity...
December 2023: Surgical Oncology
https://read.qxmd.com/read/37938837/clonal-hematopoiesis-and-cardiovascular-disease-in-patients-with-multiple-myeloma-undergoing-hematopoietic-cell-transplant
#25
JOURNAL ARTICLE
June-Wha Rhee, Raju Pillai, Tianhui He, Alysia Bosworth, Sitong Chen, Liezl Atencio, Artem Oganesyan, Kelly Peng, Tati Guzman, Kara Lukas, Brianna Sigala, Aleksi Iukuridze, Lanie Lindenfeld, Faizi Jamal, Pradeep Natarajan, Scott Goldsmith, Amrita Krishnan, Michael Rosenzweig, F Lennie Wong, Stephen J Forman, Saro Armenian
IMPORTANCE: There is a paucity of information on the association between clonal hematopoiesis of indeterminate potential (CHIP) and cardiovascular disease (CVD) in patients with cancer, including those with multiple myeloma (MM) undergoing hematopoietic cell transplant (HCT), a population at high risk of developing CVD after HCT. OBJECTIVE: To examine the association between CHIP and CVD in patients with MM and to describe modifiers of CVD risk among those with CHIP...
November 8, 2023: JAMA Cardiology
https://read.qxmd.com/read/37936977/the-impact-of-renal-impairment-in-multiple-myeloma-patients-undergoing-autologous-stem-cell-transplantation-with-melphalan-conditioning
#26
JOURNAL ARTICLE
Sorana G Ursu, Samantha Maples, Kiersten J Williams, Gina Patrus, Yazan Samhouri, Salman Fazal, Prerna Mewawalla, Santhosh Sadashiv
BACKGROUND: There are no standard renal dose adjustments for melphalan conditioning for autologous stem cell transplantation (ASCT) in multiple myeloma (MM) patients. The objective of this study was to evaluate the effect of melphalan dosing and chronic kidney disease (CKD) on transplant-related outcomes, progression-free survival (PFS), and overall survival (OS). METHODS: A retrospective chart review was performed, and MM patients who underwent ASCT between February 2016 and September 2021 were included...
October 2023: Journal of Hematology (Brossard, Quebec)
https://read.qxmd.com/read/37827881/optimization-of-metabolic-tumor-volume-as-a-prognostic-marker-in-car-t-cell-therapy-for-aggressive-large-b-cell-nhl
#27
JOURNAL ARTICLE
Alexandra E Rojek, Justin P Kline, Nicholas Feinberg, Daniel E Appelbaum, Yonglin Pu, Benjamin A Derman, Andrzej Jakubowiak, Satyajit Kosuri, Hongtao Liu, Mariam T Nawas, Sonali M Smith, Michael R Bishop, Peter A Riedell
BACKGROUND: CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has become a standard of care in relapsed/refractory (R/R) aggressive large B-cell non-Hodgkin lymphomas (B-NHL) though the majority of recipients do not receive durable disease benefit, prompting the need to better define risk factors for relapse/progression. OBJECTIVES: We performed a single-center, retrospective analysis of patients treated with commercial CAR T-cell therapy to evaluate the impact of tumor burden, as measured by whole-body metabolic tumor volume (MTV) from 18 F fluorodeoxyglucose PET imaging, on treatment outcomes...
September 16, 2023: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/37798888/kidney-transplantation-and-clinical-outcomes-in-patients-with-multiple-myeloma-evidence-from-the-united-states-nationwide-inpatient-sample
#28
JOURNAL ARTICLE
Bo Yang, Lijuan Zhang, Xuechun Lu
PURPOSE: Patients with multiple myeloma (MM) are prone to developing persistent renal insufficiency. Novel therapeutic medications have improved long-term survival, making kidney transplantation (KT) a viable treatment option for MM survivors with end-stage renal disease. This study aimed to investigate the clinical outcomes in patients with MM who have received KT. METHODS: Data from hospitalized patients ≥ 40 years of age with MM in the Nationwide Inpatient Sample 2016-2018 of the United States were queried...
September 2023: International Neurourology Journal
https://read.qxmd.com/read/37784286/radiation-in-a-new-era-of-multiple-myeloma-management-patterns-of-utilization-clinical-radiologic-and-biochemical-outcomes-and-possible-genomic-correlates-of-response
#29
JOURNAL ARTICLE
A Dreyfuss, B Fregonese, J Ma, R R Sarkar, J Lee, G Cederquist, H G Hubbeling, K R Tringale, N A Wijetunga, S Usmani, C Hajj, B S Imber, J Yahalom
PURPOSE/OBJECTIVE(S): Systemic therapies for multiple myeloma (MM) have advanced considerably, improving patient outcomes. Yet, the use of radiotherapy (RT) has remained heterogeneous, and even controversial, due to minimal data on outcomes. With the ultimate goal of guiding the design of prospective trials incorporating RT, we initiated a study of our institutional experience treating MM with RT since 1/1/2000. Here we report a preliminary feasibility analysis of an initial sample cohort, identifying patterns of RT utilization, outcomes, and impact of RT on radiographic and biochemical markers, with genomic characterization for more recently treated patients...
October 1, 2023: International Journal of Radiation Oncology, Biology, Physics
https://read.qxmd.com/read/37737970/risk-of-thromboembolic-events-associated-with-different-multiple-myeloma-regimens-in-taiwan-a-nested-case-control-study
#30
JOURNAL ARTICLE
Mei-Tsen Chen, Shih-Tsung Huang, Huai-Hsuan Huang, Wen-Jone Chen, Bor-Sheng Ko, Fei-Yuan Hsiao
Although novel agents for multiple myeloma (MM) have a better response rate and survival in both newly diagnosed and relapsed/refractory MM patients, concerns regarding the association between MM treatments and thromboembolic events have been raised. The aim of this population-based study was to examine the association between different combinations of MM treatments and the risk of thromboembolic events. We conducted a nested case-control study using the Taiwan Cancer Registry (TCR) and National Health Insurance Research Database (NHIRD)...
November 2023: Journal of Thrombosis and Thrombolysis
https://read.qxmd.com/read/37722828/occupational-exposure-to-extremely-low-frequency-magnetic-fields-and-follicular-lymphoma-risk-a-family-case-control-study
#31
JOURNAL ARTICLE
Michael K Odutola, Marina T van Leeuwen, Fiona J Bruinsma, Geza Benke, Michelle C Turner, Judith Trotman, Jennifer Turner, John F Seymour, H Miles Prince, Samuel T Milliken, Campbell Tiley, Mark Hertzberg, Fernando Roncolato, Stephen Opat, Robert Lindeman, Emma Verner, Craig R Underhill, Elisabeth Cardis, Graham Giles, Claire M Vajdic
OBJECTIVES: We aimed to examine the relationship between occupational exposure to extremely low-frequency magnetic fields (ELF-MFs) and follicular lymphoma (FL) risk. METHODS: We conducted a family case-control study between 2011 and 2016 in Australia and included 681 cases. Controls were either a family member of cases (related (n=294), unrelated (n=179)) or were unrelated recruited for a similarly designed Australian multiple myeloma study (n=711). We obtained detailed job histories using lifetime work calendars...
September 18, 2023: Occupational and Environmental Medicine
https://read.qxmd.com/read/37708911/addition-of-daratumumab-to-lenalidomide-bortezomib-and-dexamethasone-for-transplantation-eligible-patients-with-newly-diagnosed-multiple-myeloma-griffin-final-analysis-of-an-open-label-randomised-phase-2-trial
#32
RANDOMIZED CONTROLLED TRIAL
Peter M Voorhees, Douglas W Sborov, Jacob Laubach, Jonathan L Kaufman, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Rebecca Silbermann, Luciano J Costa, Larry D Anderson, Nitya Nathwani, Nina Shah, Naresh Bumma, Yvonne A Efebera, Sarah A Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M Wildes, Robert Z Orlowski, Kenneth H Shain, Andrew J Cowan, Shira Dinner, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S Lin, Saad Z Usmani, Paul G Richardson
BACKGROUND: Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone (D-RVd) in the GRIFFIN study improved the stringent complete response rate by the end of consolidation in transplantation-eligible patients with newly diagnosed multiple myeloma. Here, we report the findings of the predefined final analysis. METHODS: GRIFFIN was an open-label, randomised, active-controlled, phase 2 trial done in 35 research centres in the USA. Patients had newly diagnosed multiple myeloma with measurable disease by M protein or free light chain, were aged 18-70 years, had an ECOG performance score of 0-2, and were eligible for autologous haematopoietic stem-cell transplantation (HSCT)...
October 2023: Lancet Haematology
https://read.qxmd.com/read/37690903/geographic-disparity-of-outcome-in-patients-with-cancer-over-decades-the-surveillance-epidemiology-and-end-results
#33
JOURNAL ARTICLE
Koji Sasaki, Kiyomi Morita, Hagop Kantarjian, Guillermo Garcia-Manero, Elias Jabbour, Farhad Ravandi, Marina Konopleva, Gautam Borthakur, William Wierda, Naval Daver, Koichi Takahashi, Courtney DiNardo, Guillermo Montalban Bravo, Ghayas C Issa, Sherry A Pierce, Kelly A Soltysiak, Martha S Tingen, Jorge E Cortes
BACKGROUND: Improvements in prevention, early detection, and effective cancer therapy have decreased cancer-related mortality; however, significant health disparities exist. Therefore, we investigated the impact of these disparities on survival. METHODS: In the Surveillance, Epidemiology, and End Results, we identified 784,341 patients with cancer between 1990 and 2016 in Georgia, 68,493 between 1990 and 1999; 371,353 between 2000 and 2009; and 322,932 between 2010 and 2016...
August 6, 2023: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/37684184/a-meta-analysis-of-the-efficacy-of-pomalidomide-based-regimens-for-the-treatment-of-relapsed-refractory-multiple-myeloma-after-lenalidomide-exposure
#34
JOURNAL ARTICLE
Faith E Davies, Xavier Leleu, Prisca Vogel, Sujith Dhanasiri, Pauline Le Nouveau, Katja Weisel
INTRODUCTION: The objective was to assess the benefit of pomalidomide-based combination regimens in patients with relapsed/refractory multiple myeloma (RRMM) previously treated with lenalidomide. A pooled estimate was obtained for efficacy outcomes including overall response rate (ORR), complete response (CR) rate, and progression-free survival (PFS) based on multiple trials conducted in this patient population. PATIENTS AND METHODS: A literature search was conducted on March 22, 2022 for relevant trials published between January 1, 2016 and the search date...
November 2023: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/37667498/modifiable-lifestyle-risk-factors-and-survival-after-diagnosis-with-multiple-myeloma
#35
JOURNAL ARTICLE
Simon Cheah, Julie K Bassett, Fiona J Bruinsma, John Hopper, Harindra Jayasekara, Doug Joshua, Robert J MacInnis, H Miles Prince, Melissa C Southey, Claire M Vajdic, Marina T van Leeuwen, Nicole Wong Doo, Simon J Harrison, Dallas R English, Graham G Giles, Roger L Milne
BACKGROUND: While remaining incurable, median overall survival for MM now exceeds 5 years. Yet few studies have investigated how modifiable lifestyle factors influence survival. We investigate whether adiposity, diet, alcohol, or smoking are associated with MM-related fatality. RESEARCH DESIGN AND METHODS: We recruited 760 incident cases of MM via cancer registries in two Australian states during 2010-2016. Participants returned questionnaires on health and lifestyle...
September 4, 2023: Expert Review of Hematology
https://read.qxmd.com/read/37628464/drug-expenditure-price-and-utilization-in-us-medicaid-a-trend-analysis-for-new-multiple-myeloma-medications-from-2016-to-2022
#36
JOURNAL ARTICLE
Marwan Alrasheed, Abdulrahman Alsuhibani, Bander Balkhi, Jeff Jianfei Guo
INTRODUCTION: Multiple myeloma (MM) is the most common plasma cell tumor type. In late 2015, the FDA approved three new medications for MM. These medications were ixazomib, daratumumab, and elotuzumab. However, their utilization, reimbursement, and price in the Medicaid program have not been analyzed before. METHODS: A retrospective drug utilization study using the national Medicaid pharmacy claims data from 2016 to 2022 in the US. The primary metrics of analysis were utilization (number of prescriptions), reimbursement (total spending), and price (reimbursement per prescription)...
August 11, 2023: Healthcare (Basel, Switzerland)
https://read.qxmd.com/read/37573150/characteristics-and-outcome-of-infectious-complications-after-autologous-hematopoietic-cell-transplantation-in-multiple-myeloma-patients
#37
JOURNAL ARTICLE
Aditya Jandial, Deepesh Lad, Arihant Jain, Alka Khadwal, Charanpreet Singh, Gaurav Prakash, Vikas Suri, Sreejesh Sreedharanunni, Man Updesh Singh Sachdeva, Pallab Ray, Neelam Varma, Subhash Varma, Pankaj Malhotra
BACKGROUND: Infections are a significant cause of morbidity and mortality after autologous hematopoietic cell transplantation (AHCT) in multiple myeloma (MM) patients. There has been a rapid advancement and evolution in MM treatment landscape in the last decade. There is limited information on post-AHCT infectious complications among MM patients with or without levofloxacin prophylaxis from developing countries. MATERIALS AND METHODS: We performed a retrospective study to explore the incidence, pattern, and clinical outcome of infections following AHCT in MM patients from 2010 to 2019 at our center...
August 12, 2023: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://read.qxmd.com/read/37554170/impact-of-interval-progression-before-autologous-stem-cell-transplant-in-patients-with-multiple-myeloma
#38
JOURNAL ARTICLE
Alicia Bao, Qiuhong Zhao, Ruchi Kudalkar, Jose Rodriguez, Nidhi Sharma, Naresh Bumma, Srinivas S Devarakonda, Abdullah M Khan, Elvira Umyarova, Ashley E Rosko, Don Benson, Francesca Cottini
In transplant-eligible patients who undergo upfront autologous stem cell transplant (ASCT) for multiple myeloma (MM), standard practice is to treat with six to eight cycles of induction therapy followed by high-dose chemotherapy with ASCT. A gap between the end of induction and the day of ASCT exists to allow stem cell mobilization and collection. Despite attempts to limit the length of this interval, we noticed that some patients experience interval progression (IP) of disease between the end of induction therapy and the day of ASCT...
2023: Frontiers in Oncology
https://read.qxmd.com/read/37543712/carfilzomib-lenalidomide-and-dexamethasone-followed-by-a-second-asct-is-an-effective-strategy-in-first-relapse-multiple-myeloma-a-study-on-behalf-of-the-chronic-malignancies-working-party-of-the-ebmt
#39
JOURNAL ARTICLE
Rémi Tilmont, Ibrahim Yakoub-Agha, Diderik-Jan Eikema, Nienke Zinger, Mathias Haenel, Nicolaas Schaap, Concepcion Herrera Arroyo, Christine Schuermans, Britta Besemer, Monika Engelhardt, Jürgen Kuball, Mariagrazia Michieli, Natalie Schub, Keith M O Wilson, Jean Henri Bourhis, Maria Victoria Mateos, Neil Rabin, Edgar Jost, Nicolaus Kröger, José M Moraleda, Tommaso Za, Patrick J Hayden, Meral Beksac, Donal Mclornan, Stefan Schönland, Salomon Manier
In the setting of a first relapse of multiple myeloma (MM), a second autologous stem cell transplant (ASCT) following carfilzomib-lenalidomide-dexamethasone (KRd) is an option, although there is scarce data concerning this approach. We performed a retrospective study involving 22 EBMT-affiliated centers. Eligible MM patients had received a second-line treatment with KRd induction followed by a second ASCT between 2016 and 2018. Primary objective was to estimate progression-free survival (PFS) and overall survival (OS)...
November 2023: Bone Marrow Transplantation
https://read.qxmd.com/read/37522153/validation-of-a-diagnostic-model-to-differentiate-multiple-myeloma-from-bone-metastasis
#40
JOURNAL ARTICLE
Phichayut Phinyo, Nutcha Jarupanich, Lalita Lumkul, Areerak Phanphaisarn, Thanate Poosiripinyo, Sermsak Sukpanichyingyong, Pichaya Thanindratarn, Yodsawee Pornmeechai, Taweechok Wisanuyotin, Rapin Phimolsarnti, Ekarat Rattarittamrong, Dumnoensun Pruksakorn
PURPOSE: A diagnostic model to differentiate multiple myeloma (MM) from bone metastasis (BM) in patients with destructive bone lesions (MM-BM DDx) was developed to promote timely and appropriate referral of patients with MM to hematologists. External validation has never been conducted. This study aims to externally validate the performance of the MM-BM DDx model. PATIENTS AND METHODS: This multi-center external validation study was conducted using retrospective data of patients over 45 years old diagnosed with MM or BM at six university-affiliated hospitals in Thailand from 2016 to 2022...
2023: Clinical Epidemiology
keyword
keyword
164686
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.